{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:04:59Z","timestamp":1789765499384,"version":"4.0.1"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cjca.2026.08.010","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:59:44Z","timestamp":1787727584000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Viewpoint: Which Patient Is a VESALIUS-CV Patient? Rethinking Primary and Secondary Prevention"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2419-1476","authenticated-orcid":false,"given":"G.B. John","family":"Mancini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2026.08.010_bib2","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2026.08.010_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2514428","article-title":"Evolocumab in patients without a previous myocardial infarction or stroke","volume":"394","author":"Bohula","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.08.010_bib4","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1016\/j.jacc.2026.02.4869","article-title":"Clinical guidelines as a continuous work in progress: moving at the speed of science","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2026.08.010_bib5","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 Focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2026.08.010_bib6","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2026.08.010_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ahj.2023.12.004","article-title":"Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial","volume":"269","author":"Bohula","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2026.08.010_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.126.080616","article-title":"Evolocumab in patients with prior percutaneous coronary intervention and no prior myocardial infarction: results from the VESALIUS-CV trial","volume":"154","author":"Bergmark","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2026.08.010_bib9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.atherosclerosis.2017.06.006","article-title":"Detection of atherosclerotic cardiovascular disease influences the perceived need for aggressive lipid management","volume":"263","author":"Mancini","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2026.08.010_bib10","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1056\/NEJMoa2600283","article-title":"Intensive LDL cholesterol targeting in atherosclerotic cardiovascular disease","volume":"394","author":"Lee","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2026.08.010_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.100886","article-title":"Canadian cost-effectiveness of coronary artery calcium screening based on the Multi-Ethnic Study of Atherosclerosis","volume":"3","author":"Qureshi","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.cjca.2026.08.010_bib12","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1001\/jama.2026.3277","article-title":"Evolocumab to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes: results from the VESALIUS-CV trial","volume":"335","author":"Marston","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2026.08.010_bib13","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2026.2392","article-title":"Lipid lowering in 2026: still asking when, in whom, and how","volume":"335","author":"Greenland","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2026.08.010_bib14","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.2337\/dc26-0847","article-title":"Evolocumab in patients with high-risk diabetes: results from the VESALIUS-CV trial","volume":"49","author":"Leiter","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.cjca.2026.08.010_bib15","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1161\/CIRCULATIONAHA.126.080999","article-title":"Lipoprotein(a) levels, risk of cardiovascular events, and benefit of evolocumab: findings from the VESALIUS-CV trial","volume":"153","author":"Monguillon","year":"2026","journal-title":"Circulation"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26011700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X26011700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:47:35Z","timestamp":1789764455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X26011700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":14,"alternative-id":["S0828282X26011700"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2026.08.010","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viewpoint: Which Patient Is a VESALIUS-CV Patient? Rethinking Primary and Secondary Prevention","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2026.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}